The abstract is read at the publisher; the summary is JClub's.
Biological and digital twins are positioned as human-relevant cardiometabolic drug development tools, enabling patient-scale interpretation and prediction of pharmacological parameters.
- Why it matters: Animal models can mismatch human physiology, contributing to costly translational failures such as cardiovascular toxicity withdrawals, and NAMs need validation before replacing them.
- What they did: The FDA’s 2025 NAMs roadmap authorizes submissions using human-relevant models and promotes integrated, fit-for-purpose strategies combining biological twins (human-derived in vitro systems) with digital twins trained on clinical drug response data.
- The result: Twins can assess cardiotoxicity from drug metabolites and interpret biological twin results at the patient scale, but major validation challenges remain before routine replacement of animal models.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.